Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents with Select Solid Tumors, Lymphoma, and Malignant Brain Tumors
Protocol ID
DCL-17-001
Disease (Sub Disease)
Various
Diagnosis Stage
Relapsed
Refractory
Recurrent
Location
NSW
Sponsor
Cellectar Biosciences, Inc.
Trial Status
Open
Sites
The Children's Hospital at Westmead
Study Type
Treatment
Phase
Phase 1
Age Eligibility
2 Years to 25 Years
International registry ID's
NCT03478462
Back to Registry
Study Title A Phase 1 Open-Label Dose Escalation Study of CLR 131 in Children and Adolescents with Select Solid Tumors Lymphoma and Malignant Brain Tumors
Protocol ID DCL-17-001
Disease (Sub Disease) Various
Diagnosis Stage Relapsed
Refractory
Recurrent
Location NSW
Sponsor Cellectar Biosciences, Inc.
Links https://clinicaltrials.gov/ct2/show/NCT03478462
Trial Status Open
Trial Open Date 30/04/2019
Sites The Children's Hospital at Westmead
Study Type Treatment
Phase Phase 1
Age Eligibility 2 Years to 25 Years
International registry ID's NCT03478462